

GLAXOSMITHKLINE PLC

Form 6-K

July 19, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 19 July 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes ☐ No ☒

--

GlaxoSmithKline plc

(the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy

b) Position/status SVP & General Counsel

c) Initial notification/
amendment Initial notification

Details of the issuer, emission allowance market
2. participant, auction platform, auctioneer or
auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each
3. type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

Description of American Depositary Shares
(‘ADSs’)

a) The financial
instrument ISIN: US37733W1053

b) Nature of
The transaction Increase in notional interest
in ADSs following the
re-investment of dividends
paid to shareholders on 14
July 2016 on ADSs held in
the Company's 2009
Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s)	\$43.87	898.937
and volume(s)	\$43.87	997.468
	\$43.87	1,157.246

Aggregated
information

d) Aggregated volume 3,144.651 ADSs
Price \$43.87

e) Date of the
transaction 2016-07-14

Place of
f) the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: July 19, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc